iCAD Inc. (ICAD)

3.42
NASDAQ : Electronic Technology
Prev Close 3.42
Day Low/High 0.00 / 0.00
52 Wk Low/High 2.93 / 6.07
Avg Volume 32.60K
Exchange NASDAQ
Shares Outstanding 16.60M
Market Cap 53.30M
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ICAD Announces Approval Of Xoft® Axxent® Balloon Applicators By China Food & Drug Administration For Treatment Of Early-Stage Breast Cancer

ICAD Announces Approval Of Xoft® Axxent® Balloon Applicators By China Food & Drug Administration For Treatment Of Early-Stage Breast Cancer

Availability of full suite of Xoft System products in China represents significant milestone in expanding global access to advanced technology to treat range of cancers

ICAD Announces Positive Study Results Comparing Use Of Company's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® To Mohs Surgery In Treatment Of Early-stage Non-melanoma Skin Cancer

ICAD Announces Positive Study Results Comparing Use Of Company's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® To Mohs Surgery In Treatment Of Early-stage Non-melanoma Skin Cancer

Results of breakthrough study published in peer-reviewed Journal of Contemporary Brachytherapy showed no statistically significant difference in recurrence of cancer at mean follow-up of 3.4 years

Carolina Breast Imaging Specialists Adopts ICAD's Advanced Artificial Intelligence Technology For Digital Breast 3D Tomosynthesis

iCAD's revolutionary PowerLook® Tomo Detection deep learning solution helps radiologists identify breast cancer more efficiently

First-Ever European Analysis Of Electronic Brachytherapy Using The Xoft System For Endometrial And Cervical Cancer Treatment To Be Presented At European Society For Radiotherapy & Oncology Meeting

Preliminary results show targeted treatment offers low toxicity for patients with endometrial or cervical cancer

ICAD Announces First Early-Stage Breast Cancer Patient Treated With Intraoperative Radiation Therapy Using The Xoft System At Monash Cancer Centre, A Partnership Between Peter MacCallum Cancer Centre And Monash Health In Australia

First installation of advanced, multi-platform Xoft System in Australia increases global access to versatile, clinically proven technology

A Portfolio of Fixed Income, Pass Throughs and Small Caps

A Portfolio of Fixed Income, Pass Throughs and Small Caps

This portfolio is designed to produce a blended yield of 6% to 8%.

TheStreet Quant Rating: D (Sell)